Key facts
- This page summarizes Patrick Taylor Horn's Form 4 filing for ALBIREO PHARMA, INC..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 25 Oct 2021, 18:41.
Patrick Taylor Horn - 22 Oct 2021 Form 4 Insider Report for ALBIREO PHARMA, INC.
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- N/A
- Reported as of
- 22 Oct 2021
- Net transaction value
- -$2,739
- SEC form
- 4
- Accepted by SEC
- 25 Oct 2021, 18:41:50 UTC
- Prior SEC filing
- 26 Jul 2021
- Next SEC filing
- 20 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason Duncan, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Taylor Horn filed Form 4 for ALBIREO PHARMA, INC. on 25 Oct 2021.
Change
- Previous filing in this sequence was filed on 26 Jul 2021.
- Current net transaction value: -$2,739.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALBO
transaction
Common Stock
Sale
- Transaction value
- $2,739
- Shares
- -95
- Change %
- -0.76%
- Price
- $28.83
- Shares after
- 12,355
- Date
- 22 Oct 2021
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $28.9187, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Footnote F3
Represents 5,292 shares of common stock and 7,063 restricted stock units.